John M. Hatcher, Ph.D.
Affiliations: | 2011 | Chemistry | Duke University, Durham, NC |
| 2012- | Cancer Biology | Dana-Farber Cancer Institute/Harvard Medical School |
Google:
"John Hatcher"Parents
Sign in to add mentor| Don M. Coltart | grad student | 2011 | Duke | |
| (An Umpolung Approach to the alpha-Functionalization of Ketones and Aldehydes.) | ||||
| Nathanael Gray | post-doc | 2012-2015 | Harvard Medical School/Dana-Farber Cancer Institute | |
| Nathanael Gray | research scientist | 2015- | Harvard Medical School/Dana-Farber Cancer Institute | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zerfas BL, Liu Y, Che J, et al. (2025) Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α. Rsc Medicinal Chemistry |
| Hatcher JM, Zwirek M, Sarhan AR, et al. (2023) Development of a Highly Potent and Selective Degrader of LRRK2. Bioorganic & Medicinal Chemistry Letters. 129449 |
| Gao Y, Jiang B, Kim H, et al. (2023) Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry |
| Chow HY, Karchugina S, Groendyke BJ, et al. (2022) Development and Utility of a PAK1-Selective Degrader. Journal of Medicinal Chemistry. 65: 15627-15641 |
| Malone CF, Kim M, Alexe G, et al. (2022) Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. Cancer Research |
| Powell CE, Hatcher JM, Jiang J, et al. (2022) Selective Macrocyclic Inhibitors of DYRK1A/B. Acs Medicinal Chemistry Letters. 13: 577-585 |
| Son J, Jang J, Beyett TS, et al. (2022) A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Research |
| Hatcher JM, Vatsan PS, Wang E, et al. (2021) Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19. Acs Medicinal Chemistry Letters. 12: 1689-1693 |
| Donovan KA, Ferguson FM, Bushman JW, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell |
| Hatcher JM, Yang G, Wang L, et al. (2020) Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. Acs Medicinal Chemistry Letters. 11: 2238-2243 |